vs
STANDARD BIOTOOLS INC.（LAB）与TRANSACT TECHNOLOGIES INC（TACT）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是TRANSACT TECHNOLOGIES INC的1.7倍（$19.6M vs $11.5M），TRANSACT TECHNOLOGIES INC同比增速更快（11.9% vs -11.5%），TRANSACT TECHNOLOGIES INC自由现金流更多（$589.0K vs $-23.1M），过去两年TRANSACT TECHNOLOGIES INC的营收复合增速更高（3.5% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
该公司相关归属主体罗珀技术公司是一家控股集团，主要投资控股科技领域的各类企业，业务覆盖多个科技细分赛道，依托旗下子公司开展多元化科技业务布局。
LAB vs TACT — 直观对比
营收规模更大
LAB
是对方的1.7倍
$11.5M
营收增速更快
TACT
高出23.4%
-11.5%
自由现金流更多
TACT
多$23.7M
$-23.1M
两年增速更快
TACT
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $11.5M |
| 净利润 | $-34.7M | — |
| 毛利率 | 48.5% | 47.6% |
| 营业利润率 | -168.5% | -10.1% |
| 净利率 | -177.4% | — |
| 营收同比 | -11.5% | 11.9% |
| 净利润同比 | -28.8% | — |
| 每股收益（稀释后） | $-0.09 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABTACT
| Q4 25 | — | $11.5M | ||
| Q3 25 | $19.6M | $13.2M | ||
| Q2 25 | $21.8M | $13.8M | ||
| Q1 25 | $40.8M | $13.1M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | $22.1M | $10.9M | ||
| Q2 24 | $22.5M | $11.6M | ||
| Q1 24 | $45.5M | $10.7M |
净利润LABTACT
| Q4 25 | — | — | ||
| Q3 25 | $-34.7M | $15.0K | ||
| Q2 25 | $-33.5M | $-143.0K | ||
| Q1 25 | $-26.0M | $19.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-26.9M | $-551.0K | ||
| Q2 24 | $-45.7M | $-319.0K | ||
| Q1 24 | $-32.2M | $-1.0M |
毛利率LABTACT
| Q4 25 | — | 47.6% | ||
| Q3 25 | 48.5% | 49.8% | ||
| Q2 25 | 48.8% | 48.2% | ||
| Q1 25 | 48.4% | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | 54.9% | 48.1% | ||
| Q2 24 | 46.1% | 52.7% | ||
| Q1 24 | 53.1% | 52.6% |
营业利润率LABTACT
| Q4 25 | — | -10.1% | ||
| Q3 25 | -168.5% | 0.1% | ||
| Q2 25 | -118.1% | -1.9% | ||
| Q1 25 | -80.8% | -0.1% | ||
| Q4 24 | — | -10.3% | ||
| Q3 24 | -120.9% | -7.7% | ||
| Q2 24 | -134.5% | -3.8% | ||
| Q1 24 | -132.2% | -12.2% |
净利率LABTACT
| Q4 25 | — | — | ||
| Q3 25 | -177.4% | 0.1% | ||
| Q2 25 | -153.7% | -1.0% | ||
| Q1 25 | -63.8% | 0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -122.0% | -5.1% | ||
| Q2 24 | -203.3% | -2.8% | ||
| Q1 24 | -70.6% | -9.7% |
每股收益（稀释后）LABTACT
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.09 | $0.00 | ||
| Q2 25 | $-0.09 | $-0.01 | ||
| Q1 25 | $-0.07 | $0.00 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-0.07 | $-0.06 | ||
| Q2 24 | $-0.12 | $-0.03 | ||
| Q1 24 | $-0.27 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $20.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $31.1M |
| 总资产 | $539.6M | $44.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABTACT
| Q4 25 | — | $20.4M | ||
| Q3 25 | $129.4M | $20.0M | ||
| Q2 25 | $158.6M | $17.7M | ||
| Q1 25 | $150.9M | $14.2M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | $210.6M | $11.3M | ||
| Q2 24 | $269.8M | $11.1M | ||
| Q1 24 | $287.1M | $10.6M |
总债务LABTACT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABTACT
| Q4 25 | — | $31.1M | ||
| Q3 25 | $399.7M | $31.8M | ||
| Q2 25 | $424.5M | $31.3M | ||
| Q1 25 | $454.6M | $30.9M | ||
| Q4 24 | — | $30.6M | ||
| Q3 24 | $489.3M | $38.4M | ||
| Q2 24 | $510.3M | $38.5M | ||
| Q1 24 | $577.3M | $38.6M |
总资产LABTACT
| Q4 25 | — | $44.8M | ||
| Q3 25 | $539.6M | $45.0M | ||
| Q2 25 | $557.0M | $44.5M | ||
| Q1 25 | $579.6M | $44.2M | ||
| Q4 24 | — | $44.0M | ||
| Q3 24 | $681.5M | $50.5M | ||
| Q2 24 | $708.7M | $50.4M | ||
| Q1 24 | $777.7M | $51.9M |
负债/权益比LABTACT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $609.0K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $589.0K |
| 自由现金流率自由现金流/营收 | -118.1% | 5.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $7.6M |
8季度趋势，按日历期对齐
经营现金流LABTACT
| Q4 25 | — | $609.0K | ||
| Q3 25 | $-22.2M | $3.6M | ||
| Q2 25 | $-20.7M | $3.6M | ||
| Q1 25 | $-30.3M | $-161.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $-27.9M | $327.0K | ||
| Q2 24 | $-39.0M | $636.0K | ||
| Q1 24 | $-62.5M | $-1.5M |
自由现金流LABTACT
| Q4 25 | — | $589.0K | ||
| Q3 25 | $-23.1M | $3.6M | ||
| Q2 25 | $-22.6M | $3.6M | ||
| Q1 25 | $-35.3M | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $-30.1M | $259.0K | ||
| Q2 24 | $-41.0M | $499.0K | ||
| Q1 24 | $-63.3M | $-1.6M |
自由现金流率LABTACT
| Q4 25 | — | 5.1% | ||
| Q3 25 | -118.1% | 27.1% | ||
| Q2 25 | -103.6% | 25.9% | ||
| Q1 25 | -86.6% | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | -136.4% | 2.4% | ||
| Q2 24 | -182.2% | 4.3% | ||
| Q1 24 | -138.9% | -14.9% |
资本支出强度LABTACT
| Q4 25 | — | 0.2% | ||
| Q3 25 | 4.5% | 0.5% | ||
| Q2 25 | 8.7% | 0.1% | ||
| Q1 25 | 12.4% | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 10.2% | 0.6% | ||
| Q2 24 | 8.6% | 1.2% | ||
| Q1 24 | 1.7% | 1.0% |
现金转化率LABTACT
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
TACT
暂无分部数据
